bioRxiv Science⌕ Search

Biology subjects

Demissie, R.

Publications and source records attributed to Demissie, R..

3 recordsLinked to original sources

High-throughput Virtual Screen of Endocrine-disrupting Chemicals Identifies Disruptors of EGFR Signaling

Chemical exposures during pregnancy are linked to an increased risk of pregnancy complications that contribute significantly to maternal and infant morbidity and mortality and can lead to long term health consequences for both the mother and the offspring. The placenta, a central regulator of pregnancy health, is a direct target of environmental toxicants. Epidermal growth factor receptor (EGFR), highly expressed in the placenta, regulates proliferation, migration, invasion, fusion, and cellular bioenergetics. To identify compounds of environmental concern with potential for EGFR-disrupting activity, we optimized a high-throughput virtual screening protocol for the identification of EGFR inhibitors and achieved enrichment factors of EF1% = 10.09, EF5% = 3.86, and EF10% = 3.0 in a benchmarking dataset. We applied this protocol to screen the Collaborative Estrogen Receptor Activity Prediction Project database, finding that top-scoring compounds were enriched for aromatic and fused-ring chemical classes, including dyes. Kinase activity assays revealed that two out of thirteen selected compounds, Vat Red 32 and Reactive Red 136, inhibited EGFR kinase activity with micromolar IC50 values. Additionally, pose refinement with molecular dynamics simulations characterized the binding interactions of Reactive Red 136 within the EGFR kinase domain, and functional assays in HTR-8/SVneo placental trophoblast cells showed that Reactive Red 136, but not Vat Red 32, partially attenuated EGF-mediated cell migration despite both compounds inhibiting EGFR kinase activity. Together, this study has generated an enriched dataset of candidate environmental EGFR modulators, with experimental validation confirming enrichment for EGFR-disrupting activity among the selected compounds. These results provide a valuable resource for toxicological studies.

pharmacology and toxicology↗

Molecular determinants of species-specific cell-cell recognition activating the class II gamete fusogen HAP2

Species-specific adhesion of complementary gametes is a prerequisite to cell fusion during fertilization. Despite its importance, the molecular mechanism underlying cell-cell recognition and membrane adhesion to drive gamete fusion is not fully understood for any organism. In the alga, Chlamydomonas, the species-specific gamete adhesion protein MAR1 guides the fusogen HAP2 into a pre-fusion conformation on mt- gametes and serves as a receptor for the FUS1 adhesion protein on mt+ gametes. Here, we show that soluble recombinant MAR1 completely blocks the HAP2-dependent gamete fusion process by binding to FUS1 on mt+ gametes and report the X-ray structure of the MAR1-FUS1 complex. In vivo gamete fusion experiments showed that mutations of key residues at the observed MAR1-FUS1 interface strongly impair adhesion, yet gamete fusion still proceeds, highlighting the efficiency of the fusion-activation process. These findings uncover the molecular architecture of a surface receptor complex whose formation releases the viral class II viral fusion-protein ortholog HAP2, allowing it to undergo its membrane-fusogenic conformational change.

cell biology↗

Discovery and characterization of highly potent and selective covalent inhibitors of SARS-CoV-2 PLpro

Coronavirus infections, such as the global COVID-19 pandemic, have had a profound impact on many aspects of our daily life including working style, economy, and the healthcare system. To prevent the rapid viral transmission and speed up recovery from the infection, many academic organizations and industry research labs have conducted extensive research on discovering new therapeutic options for SARS-CoV-2. Among those efforts, RNA-dependent RNA polymerase (RdRp) inhibitors such as Remdesivir, Molnupiravir and 3CLpro inhibitor such as Nirmatrelvir (Paxlovid) have been widely used as the therapeutic options. Given the recent emergence of several new variants that caused a resurgence of the virus, it would be beneficial to discover more diverse therapeutic options with novel anti-viral mechanisms. In this regard, PLpro has been highlighted since it, along with 3CLpro, is one of the two most important proteases that are required for SARS-CoV-2 viral processing. While 3CLpro inhibitors were extensively investigated in the light of Emergency Use Authorizations of Nirmatrelvir, PLpro inhibitors have not been thoroughly investigated even preclinically. Thus, discovery efforts on antivirals acting against PLpro will be valuable. PLpro inhibitors may exert their activity by inhibiting viral replication and enhancing the host defense system through blocking virus-induced cell signaling events for evading host immune response. In this study, we report the discovery and development of two covalent irreversible PLpro inhibitors, HUP0109 and its deuterated analog DX-027, out of our quest for novel anti-COVID 19 therapeutic agents for the past two and half years. HUP0109 selectively targets the viral catalytic cleft of PLpro and covalently modifies its active site cysteine residue (C111). Promising results from preclinical evaluation suggest that DX-027 can be developed as a potential COVID-19 treatment.

pharmacology and toxicology↗